Latest Treatment of schizophrenia Stories
Alkermes, Inc. (NASDAQ: ALKS) today announced that patients with schizophrenia now have a new administration option for RISPERDAL(R) CONSTA(R) ((risperidone) Long-Acting Injection). The U.S.
INDIANAPOLIS, Ind., Oct. 7 /PRNewswire-FirstCall/ -- Eli Lilly and Company today announced that it has resolved a multi-state investigation involving 32 states and the District of Columbia (DC) related to the sales, marketing and promotion of its antipsychotic medication Zyprexa(R) (olanzapine).
The newer drugs for treating schizophrenia have come under such a cloud that it's no surprise to learn of another setback: They work no better than an older, less expensive drug in children and adolescents .
Lundbeck has announced that the FDA has completed the initial check for completeness and accepted the new drug application on Serdolect for the treatment of schizophrenia for review.
BARCELONA, Spain, Sept. 2 /PRNewswire-FirstCall/ -- Final results from a 24-week study presented today at a major medical meeting in Barcelona suggest that investigational olanzapine long-acting injection (LAI) therapeutic doses showed a maintenance of treatment benefit for up to six months.
SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc.
Alkermes, Inc. (NASDAQ: ALKS) today announced that its partner, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), submitted a supplemental New Drug Application (sNDA) for RISPERDAL(R) CONSTA(R) ((risperidone) Long-Acting Injection) to the U.S.
WALTHAM, Mass., July 10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Janssen's Risperdal continues to be the leading first-line antipsychotic in the treatment of schizophrenia even though generic forms of the drug are already available and will dramatically affect physicians' prescribing habits due to new formulary controls on branded therapies.
The U.S. Food and Drug Administration says it's approved the first generic versions of Risperdal tablets for certain psychiatric disorders. The FDA said Risperdal (risperidone) is an anti-psychotic drug used for the treatment of schizophrenia, bipolar disorder and other psychiatric conditions.
- A trick or prank.